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Background/Objective: Durability is the main concern of aortic endografting, but it is not clear to what extent trial results
are applicable to “real world” patients. The purpose of this study was to assess the durability of a single model of aortic
endograft in an unselected population with core lab analysis of morphological changes.
Methods: Computed tomography (CT) images of patients treated with Talent Unidoc (Medtronic, Santa Rosa, Calif)
endografts from 2002 to 2006 in nine European centers with more than 1 year follow-up were centrally reviewed using
a dedicated software with multiplanar and volume reconstructions. Images were checked for aneurysm growth >5 mm,
neck enlargement>3 mm, graft migration>10 mm, endoleak, structural integrity. Morphological changes were defined
clinically relevant when associated with reintervention or aneurysm-related death.
Results: A total of 349 patients (mean age 73.8 years, 90% males) were available for analysis; 1187 CT examinations were
reviewed. Median abdominal aortic aneurysm (AAA) diameter was 56 mm (interquartile range [IQR] 49-62), neck
length 20 mm (IQR 16-30), and neck diameter 25 mm (IQR 23-26). Mean follow-up was 25 months (range 12-60
months). During the study period, 10 late deaths (1 aneurysm-related, 0.3%) with a survival rate of 89.2% at 48 months
and 33 reinterventions including 8 conversions (2.2%), 2 AAA ruptures (0.6%) and 1 (0.3%) loss of graft integrity were
recorded. Cumulative reintervention rate was 6%, 8%, 13%, and 16% at 1, 2, 3, and 4 years, respectively. According to core
lab analysis, 22 AAA grew, 169 were unchanged, and 158 shrunk, with a growing AAA rate of 3.1% patients/year. Five
growths required reintervention, one for rupture. Forty-seven (6.5% patients/year) neck enlargements, three clinically
relevant, 17 migrations (2.4% patients/year), five clinically relevant, and 70 endoleaks (9.7 % patients/year), 11 clinically
relevant, were detected.
Conclusion: Data from this real world experience monitored with a centralized imaging review show that endovascular
repair of abdominal aortic aneurysm with the latest generation of a single model of endograft is associated with low graft
thrombosis and graft fatigue, and low late aneurysm rupture and related death risks. Neck enlargement although
common after EVAR, is almost always without clinical consequences but a longer follow-up and prospective clinical
studies are advisable to confirm the present results. ( J Vasc Surg 2009;49:859-65.)Randomized trials (RCT) showed that endovascular
repair of abdominal aortic aneurysm (EVAR) is associated
with significant reductions in operative mortality but raised
substantial concerns regarding the long-term durability of
the benefit.1,2 There continues to be a 10% to 20% reinter-
vention rate,1-5 in part secondary to endoleak or graft
migration resulting in sac expansion. Furthermore, postop-
erative neck enlargement is reported in 10% to 35% of
patients, warning for loss of proximal fixation resulting in
graft instability.6-8
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doi:10.1016/j.jvs.2008.11.044Whether and to what extent the RCT concerns are
applicable to the real world of EVAR remains subject of
debate for two main reasons. (1) Accurate morphology
assessment of aortic repair after EVAR is not always system-
atically performed and maintained for the entire length of
follow-up outside RCTs or IDE trials, leading to unreliable
estimate of failure rates or other events as aneurysm growth,
migrations, etc. in mid- and long-term. (2) Most of the
criticism against EVAR durability is based on results ob-
tained with old generation grafts. EVAR is an evolving
technology and, since its first introduction, substantial im-
provement in material and design has changed the applica-
bility and results of repair.
The Talent AAA (Medtronic, Santa Rosa, Calif) en-
dograft system has been diffusely used in Europe and other
non-American countries since 1996. The design has been
changed and improved during time to encompass the ad-
verse events detected in the mid and long term with earlier
technologies. In 2002, the new Talent Unidoc (Medtro-
nic) system was established but no reports have focused on
the durability and stability of this device.
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logical changes after the new generation Talent Unidoc
device using core lab analysis of data.
METHODS
Patients treated for abdominal aortic aneurysm (AAA)
with Talent Unidoc between January 1, 2002 and October
15, 2006 and with at least 12 months follow-up were
included in the study. A total of 10 centers in Italy were
enrolled as participants in the Talent Unidoc Retrospective
Italian Study (TAURIS) group.
Full data sets and cross-sectional images of noncontrast
and contrast computed tomography (CT) scans performed
before hospital discharge and at each subsequent follow-up
interval were reported in the TAURIS database. All data
were considered “early” or “late” when occurring within
30 days or later.
Core lab review of morphological data was performed
in all patients with at least one CT scan performed during
follow-up at 12 months after the first postoperative CT
evaluation. Comparisons were made between the immedi-
ate postoperative and latest follow-up scans.
CT images of the preoperative, the early postoperative,
and at 12 months or more were sent for blind reading to a
centralized core laboratory. All CT scans were reviewed by
the same vascular surgeon (I.G. from the core lab group)
with previous tested interobserver agreement in CT AAA
measurement. Scans were obtained 1 cm above the celiac
artery to the femoral arteries. Images were analyzed using a
workstation with dedicated software for vascular recon-
structions and volume rendering analyses (Aquarius
TeraRecon Inc., San Mateo, Calif). Volumetric acquisition
for visualization of vessel anatomywas also performed using
a predefined module for vessel analysis of the target
regions-of-interest.
When DICOM format was not available (40% of the
cases), measurements were performed manually with a cal-
iper using the smallest diameter in the largest axial image.
We used the minor axis because is believed to be a more
reliable measure and is commonly used in FDA trials on
EVAR.8,9
Measurements and definitions. Length and diameter
of aortic neck, stent graft patency and integrity, evidence of
endoleak, and position of the stent graft in relation to the
native arterial vasculature (aorta, renal arteries, and superior
mesenteric artery) were assessed.
An increase or decrease of more than 5 mm in maxi-
mum aneurysm diameter compared with immediate post-
operative CT imaging at any time during follow-up or
between any two consecutive follow-up intervals was con-
sidered to be a significant change.
The proximal aortic neck was measured as the outer
diameter in theminor axis at two different levels: at the level
of the lowest renal artery and 5 mm distally.
Aortic neck dilation was defined as an increase of more
than 3 mm in diameter at follow-up examination in any of
the two abovementioned locations.For device migration, the distance from the level of the
superior mesenteric artery to the CT scan image containing
at least one half of the proximal stent was measured. Graft
migration was defined as dislocation of 10 mm or more
with respect to the immediate postoperative CT.
Endoleak was classified as types I through IV according
to standard definitions10 and in compliance with reporting
standards.11 Endoleaks were defined “persisting” when
present at two or more consecutive CT scan assessments.
All morphological changes with respect to the immedi-
ate postoperative assessment were considered clinically rel-
evant when associated with any reintervention, aneurysm
rupture, or related mortality.
Clinical evaluations are included as reported by each
center regardless of whether core lab data were available for
a visit interval.
Device. The Talent Unidoc device is a self-expanding
modular endograft system composed of serpentine-shaped
nitinol stents integrated into a woven polyester fabric. The
stents are spaced along a full-length nitinol spine; a 15 mm
long uncovered stent at the proximal end allows transrenal
or suprarenal fixation and a mini-support spring in the
exoskeleton at the proximal end of the graft reduces the risk
of graft in-folding.
The Talent Unidoc technology implies two changes
with respect to the original Talent AAA stent graft to
further improve graft durability: (1) chemical treatment of
nitinol to reduce corrosion and risk of fracture; and (2) iliac
connecting bar moved from lateral to medial position to
improve graft stability and conformability and decrease risk
of kinking and thrombosis.
Statistical analysis. Statistical analysis was performed
with SPSS software (version 11.0.1; SPSS Inc, Chicago,
Ill). The 2 and Fisher exact test were used to analyze
discrete variables. Results of categorical variables were re-
ported as frequency and percentages, whereas continuous
variables were expressed as mean and range for normally
distributed variables and median and interquartile ranges
(IQR) for skewed variables. Quantitative estimates of mor-
phological outcomes (growth, endoleak, neck enlarge-
ment, migration) were calculated as annual incidence rates
and displayed in patients/year percentages (IRann number
of events/person-year at risk). The Kaplan-Meier method
was used to assess the cumulative rates of reintervention
and graft thrombosis. Differences were reported as signifi-
cant when the P value was equal or less than .05.
RESULTS
During the study period, 557 patients with AAA un-
derwent elective repair with the Talent Unidoc device.
Patients with less than 12 months imaging were excluded
for further morphologic analysis. There were 10 (1.8%)
perioperative deaths. Twenty-four patients (4.3%) died
from nonaneurysm related causes before reaching 1 year.
Twelve patients (2.1%) who were converted to open sur-
gery before completing 1 year follow-up were excluded.
Finally, 162 (29%) additional patients did not have 1- or
12-month CT scans with adequate frames nor had CT
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When adequate follow-up imaging could not be obtained,
the patients were excluded from further analysis.
Therefore, 349 patients who completed both the postop-
erative (1-month) and at least 12-month CT scans represent
the study cohort and are the basis for all the further review of
morphology by the core lab. The mean follow-up period for
these 349 patients was 25 months (range 12-60 months).
One hundred eighty-five patients had a follow-up longer
than 24 months and 85 longer than 36 months. A total of
1187 complete CT scan series were reviewed by the core lab.
There were 24 females and 325 males. Patients ages
ranged between 45 and 90 years (mean 73.8 years). Patient
characteristic and baseline anatomical features are reported
in Tables I and II. There were 34 AUI and 315 bifurcated
grafts. The device was oversized by a mean of 12.8%, with
95 cases10%, 205 between 10% to 20%, and 4920% of
the baseline neck diameter.
During the mean follow-up period of 25 months, 10 of
the 349 patients included in the core lab analysis died, one
for aneurysm rupture (0.3%). Two patients died from car-
diopulmonary complications, six from cancer, and one
from stroke. The cumulative survival rate at 48 months was
89.2%. Morphological outcome for these patients was eval-
uated until the time of death.
Overall, two AAA late ruptures (0.6%) were recorded,
one fatal.
Fourteen (4%) early (within 30 days) reinterventions
(seven endovascular) were recorded, including eight (2.3%)
for limb graft thrombosis. These data are detailed in Table III.
Nineteen late (30 days) reinterventions were per-
formed, 8 (2.2%) were conversions to open repair, 3
femoro-femoral crossover bypass, and the other 8 were
performed by endovascular route. Causes, details and types
Table I. Risk factors of 349 patients
N %
Smoking 248 71
Hypertension 280 80
Hypercholesterolemia 206 59
Coronary artery disease 237 68
COPD 216 62
Diabetes 47 13
Renal disease 58 17
Cerebrovascular disease 108 31
COPD, Chronic obstructive pulmonary disease.
Table II. Anatomical features of 349 patients
Median IQR
AAA diameter (mm) 56 50-62
Neck length (mm) 20 16-30
Neck diameter (mm) 25 23-26
Neck thrombus 150 (43%) —
Neck angulation  60° 29 (8%) —
AAA, Abdominal aortic aneurysm; IQR, interquartile range.of late reintervention are shown in Table IV.The incidence of any reintervention was 6% at 1 year,
8% at 2 years, 13% at 3 years, and 16% at 4 years. The
corresponding Kaplan Meier estimates for freedom from
reintervention rate (87% at 3 years and 73.9% at 4 years)
and conversion rate are shown in Figs 1 and 2, respectively.
Morphological analysis. According to the core lab
Fig 1. Freedom from reinterventions.
Table III. Perioperative reinterventions
Perioperative reinterventions
(n  14) N Indication
Fem-fem bypass 5 Iliac limb occlusion
Iliac angioplasty 3 Iliac limb occlusion
Iliac-femoral bypass 1 Iliac limb occlusion
Aorto-monoiliac endografting 1 Type I endoleak
Hypogastric artery
embolization  distal cuff
1 Type II hypogastric
endoleak
Aneurysmal sac embolization 1 Type II endoleak
Spleno-renal bypass 1 Renal artery occlusion
Percutaneous hematoma drainage 1 Retroperitoneal bleeding
Table IV. Late reinterventions
Late reinterventions
(n  19) N Indication
Conversion to OR 8 1 (type 3  growth), 1 (migration 
growth), 1 (migration  type 2),
1 (rupture, neck enlargement 
growth  type 3), 1 (rupture, type
1), 1 (migration  neck
enlargement), 1 (migration), 1
type 1)
Fem-fem by-pass 3 Iliac limb occlusion
Distal cuff 3 Distal type I endoleak
Proximal cuff 1 Migration  proximal type 1
endoleak
Renal artery stenting 1 Renal artery stenosis
Aneurysmal sac
embolization
2 Type II endoleak
Aorto-monoiliac
endografting
1 Type I endoleak
OR, Open repair.reanalysis of data, the median aneurysm diameter was 56
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48mm (IQR 39-54) at the latest examination (P .0001).
The maximum aneurysm diameter remains unchanged in
169 patients (48%) and decreased 5 mm in size in other
158 patients (45%). For 22 (6.3%) aneurysms, an increase
5 mm in diameter was detected for an overall growing
AAA rate of 3.1% patients/year. In nine, AAA growth was
10 mm or more, and in 13 between 5 and 10 mm. All 22
aneurysms that enlarged were associated with one or more
complications revealed on CT scan: 17 endoleaks, 2 migra-
tions, 4 neck enlargements, and 1 graft thrombosis.
On the baseline assessment CT scan, aortic neck was 25
mm (IQR 23-26 mm) median diameter and 20 (IQR
16-30 mm) median length. Proximal neck diameter re-
mained unchanged in 302/349 patients and increased 3
mm in 47/349 patients during the following assessment.
Theoverall annual incidence rate forneckenlargementwas 6.5%
patients/year. In 20 patients, the enlargement was greater
than 5 mm.
Seventeen grafts migrated for 10 mm or more during
follow-up. The overall migration rate was 2.4% patients/
year.
Eighty-two (23.4%) endoleaks were present at the im-
mediate postoperative scan, 70 of type II, while 65 (18%)
endoleaks were detected on the latest CT scan assessment,
50 of type II. Fifty-one endoleaks were persisting.
Overall, 13 limb graft thromboses occurred, eight early
at the time of deployment and five (1.4%) later (30 days).
According to Kaplan Meier estimates, freedom from graft
limb occlusion rate was 95.6% at 5 years (Fig 3). Finally, a
single case of loss of graft integrity due to a hole in the graft
was also detected during follow-up CT assessment.
Morphological changes detected by core lab were com-
pared with clinical events recorded by each participating
center during the same period. Of the 22 aneurysm
growths 5 mm detected by the core lab, five were fol-
lowed by reintervention, one due to aneurysm rupture
(stent graft disconnection associated with endoleak). The
only case of loss of graft integrity required conversion
Fig 2. Freedom from conversion.because of aneurysm rupture. Overall, 3/47 neck enlarge-ments, 5/17 migrations, and 11/70 endoleaks were clini-
cally relevant and associated with reintervention/conversion.
DISCUSSION
This is the first multicenter experience performed out-
side IDE or RCT that used a centralized core lab analysis to
assess morphological changes after EVAR using a single
model device in a postmarketing approval setting. The
findings of the study are therefore generalizable to the “real
world” population of patients undergoing EVAR.
All available CT scans from patients with the new
generation Talent device implanted in separate vascular
centers were archived for rigorous assessment in a central-
ized core laboratory. Core lab interpretation was used
because it has a uniform methodology across sites. A stan-
dardized measurement protocol was designed to give the
most accurate measurements of the aortic and stent graft
morphology using a workstation with dedicated software
for vascular reconstructions and volume rendering analyses.
The use of automated reconstruction software and the
training of the operator in manual or semiautomated mea-
surements utilizing precise protocol improved the reliabil-
ity of the study findings (Figs 4 and 5). Although DICOM
reconstructions were not available in about 40% of the
study cohort, and thus, in these, the measurements were
performed directly from the CT image without centerline
reconstruction, all study measurements were made by a
single individual, limiting measurement variability and
minimizing any effect on our results.
Our results showed that, as advised by RCT on EVAR
durability, morphological changes in native anatomy after
EVAR are common and probably inevitable. In spite of
this, these changes can be seldom translated in stent graft
failure with last generation devices. In particular, complica-
tion rates directly related to the graft structure, as limb
occlusion or stent fracture, appeared to be significantly
lower than those shown in previous studies reporting re-
sults of older generation endografts.
It is known that the infrarenal aortic neck in AAA tends
to dilate and enlargements have been reported after EVAR
Fig 3. Freedom from graft limb occlusion.of 10% to 35%.6-8
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dilatation of aortic neck after EVAR, with an initial dilata-
tion related to device oversizing and a progressive dilatation
thereafter.12 Rodway et al reported that changes in the area
of aortic neck were significantly greater after 67 EVAR than
Fig 4. Volume rendering analysis (TeraRecon software) 24
months after endovascular aneurysm repair (EVAR) in patient
with angulated proximal neck.
Fig 5. Volume rendering analysis with aneurysmal sac evaluation
(TeraRecon software) 12 months after endovascular aneurysm
repair (EVAR).after 56 open repairs in a subset of patients included in theEVAR trial.13 Furthermore, in the EVAR subset, the me-
dian neck area significantly increased (0.7 cm2) in many
patients (68%, 31/45) within 3 months, and additional
increases occurred in more than a third (40%, 18/45) of
patients after 3 months and up to 2 years. Unfortunately,
the authors did not include any information about migra-
tion or clinical events related to these changes.
There is a clear association between neck enlargement
andmigration with literature data reporting that endografts
migrated at a 10% to 40% rate.6,8,14,15 Resch et al docu-
mented that 50% of patients with migration had significant
neck enlargemen,15 while we reported that 27% of patients
with significant neck enlargement had graft migration.6
The observations regarding aortic neck dilatation and
migration after EVAR were investigated in the TAURIS
study through core lab measurements. We used 3 mm as a
cut-off for significant neck enlargement in proximal neck
diameter. Core lab analysis of data showed that aortic neck
remained unchanged in 86% (302/349) of patients and
increased3 mm (12%) in 13% (47/349) of patients at a
maximum follow-up of 5 years. Accordingly, enlargement
of more than 3 mm occurred in 6.7% patients/year after
repair. However, this finding did not translate into a loss of
fixation, probably due to graft oversizing and stability of
proximal attachment zone.
In this regard, recently published data from a subset of
patients included in EVAR 1 Trial, warning on an increased
aortic neck dilation after EVAR rather than after open
surgery, may be clinically irrelevant.13 Indeed, in the
present study, only three of 47 neck enlargements were
associated with migration and there were few clinically
detectable migrations (5/349). However, this lack of
effect awaits confirmation by longer and larger studies. The
overall migration rate (2.4% patients/year) in TAURIS is
higher than that recently reported in other FDA trials with
new generation devices.
The comparison of the Talent and Zenith Cook (Biae-
verskow, Denmark) suprarenal devices in the patients ran-
domized in the EVAR 1 trial showed that complications
such as migration (2.7% vs 0.6%) or type I endoleak (4.8%
vs 2.5%) were more frequent in the Talent group.16 How-
ever, the difference was not significant and could be as-
cribed at least in part to different anatomical settings,
rendering the comparison between graft-specific results
unreliable. The selection of size, morphology, length, and
angulation of aneurysm necks is a relevant factor in deter-
mining the risk of progressive neck enlargement and stabil-
ity of endograft fixation, together with endograft oversiz-
ing. Indeed, data from the Zenith trial showed 14.1%
migration at 12 months in patients with 30% oversizing,
these findings were not confirmed in TAURIS.8
Loss of adherence of stringent anatomic criteria makes
the comparison between our “common world” results and
other published results on last generation devices within
FDA or IDE trials poor. Indeed according to both the
Excluder (W.L. Gore and Associates, Flagstaff, Ariz) and
the Cook Zenith (Cook Inc., Bloomington, Ind) multi-
center trials on last generation devices, the risk of migration
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Zenith (99.6% freedom from) and no migration in 235
Excluder grafts, followed only for 12 months.8,9 This ex-
ceptional low risk of migration is optimistically achievable
in common patients.
In the EUROSTAR registry, where less stringent crite-
ria were used, the migration rate was more similar to ours
and was sensibly affected by adverse anatomy, ranging from
4.3% to 5.9% according to the presence or not of an adverse
neck angulation.6 Other studies showed that the applica-
tion of commercially available devices outside specific in-
struction for use had an incremental negative effect on late
results, with difference in outcomes that are non device-
specific.17
Other studies report variable migration rates with
newer generation grafts: a recent single center experience
from Badger et al found no difference in migration rates
between 29 patients treated with Zenith and 33 with
Talent, both being as high as 17% at 3 years.18
Donayre et al in their institutional IDE clinical trial
found 7 migrations over 47 Talent implanted in adverse
neck anatomy in the period 1998-2001 and only one
migration in 48 patients enrolled after 2002 using the
newer generation LPS Talent.19
The high rate of reintervention after repair has often
been recognized as the Achilles’ heel of EVAR durabil-
ity,1-3,20 however, this is not the case if only minor, low risk
reinterventions are required to ensure the primary goal to
prevent AAA rupture and related death. The current ver-
sion of Talent Unidoc stent graft included improvements as
chemically imprinted nitinol and medial placement of the
connecting bar implemented to improve fatigue resistance.
In this series only one aneurysm-related death (0.3%) and
two AAA ruptures (0.6%) after repair occurred during a
mean follow-up of 25 months in 349 patients who were
reviewed by the core lab. In addition, the need for late
conversion to open repair was as low as 2.2% probably
because of the fewer failures of substantial graft material
fatigue.
Indeed, a number of complications related to graft
material, identified in previous studies with older genera-
tion Talent device, were less frequently encountered in the
TAURIS experience. In the TAURIS study, although free-
dom from reintervention rate was 78.4% at 5 years the
reasons for reinterventions were not attributable to graft
material weakness. Only one loss of graft integrity (0.3%)
occurred and there was no longitudinal bar erosion or
fracture for a crude rate of late graft thrombosis of 1.4%.
The overall freedom from graft limb occlusion at 5 years
(95.6%) was comparable to those showed within FDA trials
of other last generation devices and also better than that
reported in other non-FDA studies.8-9 TAURIS results
may support other experiences showing a superior patency
in Talent devices. Within the EVAR 1 trial, thrombosis/
stenosis rates were 3.8% with Zenith vs 1.1% with Talent
devices.16 Abbruzzese et al analyzed outcomes of three
commercially available devices other than Talent (Cook
Zenith [Cook Inc.], Excluder [W.L. Gore and Associates],or AneuRx [Medtronic, Santa Rosa, Calif]) applied outside
the anatomical instruction for use, and showed that the
5-year freedom from graft related adverse event was 74%
and was mainly affected by the high incidence of graft
thrombosis.17
Limitations of the study. The TAURIS study retro-
spectively analyzed patients compliant with a minimum
1-year follow-up and complete sequential imaging, thus
selection biases could not be avoided. Even if more repre-
sentative of a real world population with respect to clinical
trial, our patients were the results of a selection and there-
fore generalization of our results should be interpreted with
caution.
The study was also limited to patients in whom a device
had been successfully deployed. Therefore, we cannot an-
alyze the overall effect on clinical outcomes.
Morphological suitability was not homogenous among
centers, as it is in prospective studies with predefined crite-
ria, but this can render the results of the present experience
even more realistic and express the true outcomes of EVAR
treatment in standard settings. Morphology status was
determined in 40% on direct measurements from original
CT scan hard copies without centerline reconstruction.
This reflects the real world where many centers lack of
digitally archivedDICOM images.However, all studymea-
surements were made by a single individual, which should
limit measurements variability and thus minimize any affect
on our conclusion.
Core lab morphologic interpretation is being reported
because it has uniform methodology across the sites. How-
ever, clinical evaluations are included regardless of whether
core lab data were available for a visit interval. Due to the
recent introduction of the last generation of Unidoc tech-
nology, follow-up length could be assessed only at a mean
of 25 months.
CONCLUSIONS
Data from this real world experience monitored with a
centralized imaging review show that AAA endovascular
repair with the latest generation of a single model of en-
dograft is associated with low thrombosis and graft fatigue,
and low aneurysm rupture and related death risks. Neck
enlargement, and other morphology changes are common
after EVAR, but might be almost always without clinical
consequences. Longer follow-up is advisable to confirm the
present results.
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APPENDIX. TAURIS Study Group
Coordinating Center
Perugia: Piergiorgio Cao, Paola De Rango, Gustavo
Iacono, Giuseppe Panuccio, Gianbattista Parlani, Fabio
Verzini.
Core Lab analysis
Gustavo Iacono, Lydia Romano.
Participating Centers
Luciano Carbonari, Andrea Angelini, Ospedale di An-
cona, Ancona; Luciano Pedrini, Luigi Sensi, Ospedale
Maggiore, Bologna; Stefano Bonardelli, Marco Gardani,
Edoardo Cervi, AziendaOspedaliera Spedali Civili, Brescia;
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pedaliera Carlo Poma, Mantova; Pierfranco Salcuni, Ales-
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Giuseppe Bianchi, Rocco Giudice, Azienda Ospedaliera S.
Giovanni Addolorata, Roma; Carlo Setacci, Francesco
Setacci, Università di Siena, Policlinico Le Scotte, Siena;
Roberto Adovasio, Laura Ukovich, Ospedali Riuniti di
Trieste, Trieste.
